US Stock Market News | Monkeypox + HIV Product Demand Increases, Trinity Biotech Soars 44% After Hours
Trinity Biotech's stock price rose by 44% after hours on Monday, as the company raised its sales guidance for 2024 and expanded production capacity for HIV testing and smallpox products. It is expected that sales of HIV testing products will increase from $8 million to $10 million. Additionally, the outbreak of smallpox has prompted the company to increase the production capacity of virus transport media. Smallpox has been declared an international public health emergency by the World Health Organization
According to the Zhītōng Finance APP, Trinity Biotech (TRIB.US) saw its stock price rise by 44% after hours on Monday. Prior to this, the diagnostic company had raised its sales guidance for 2024 and stated that it was increasing production capacity.
Trinity Biotech stated that due to increased demand, the company has expanded the production capacity of its TrinScreen HIV testing product and raised its sales forecast for this product in 2024 from $8 million to $10 million.
According to a statement, the company has also increased the production capacity of its FlexTrans virus transport medium in anticipation of increased demand due to an outbreak of monkeypox.
The World Health Organization recently announced that an outbreak of monkeypox, due to a more easily transmissible variant of the virus, constitutes an "internationally concerning public health emergency."
Developers of monkeypox vaccines include Tonix Pharmaceuticals (TNXP.US), Bavarian Nordic (BVNRY.US), and GeoVax Labs (GOVX.US), while Emergent BioSolutions (EBS.US) has received approval for a vaccine and therapy targeting smallpox (which is related to the monkeypox virus).
Suppliers of monkeypox testing products and services include LabCorp (LH.US), Quest Diagnostics (DGX.US), Co-diagnostics (CODX.US), Roche (RHHBY.US), Abbott (ABT.US), and Applied DNA Sciences (APDN.US)